Microsatellite instability

Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)

Retrieved on: 
星期四, 四月 25, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Molecule, MSI, Werner syndrome, Roche, DNA, WRN, Therapy, DSM-IV codes, Microsatellite instability, Drug development, Drug discovery, Cancer, Development, Head, Pharmaceutical industry

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature.

Key Points: 
  • Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature.
  • The publication, “Chemoproteomic Discovery of a Covalent Allosteric Inhibitor of WRN Helicase,” by Kristen Baltgalvis et al, published jointly with our partner Roche, speaks to the chemical proteomic-enabled discovery of a clinical-stage, covalent allosteric inhibitor of Werner helicase (WRN), VVD-133214 (RO7589831), and further confirms Vividion’s approach to discovering and developing novel therapeutics.
  • “Vividion discovered covalent ligands targeting a novel allosteric pocket on WRN, a well- known but challenging therapeutic target in drug development.
  • The WRN molecule was identified under the collaboration agreement entered between Vividion and Roche in 2020.

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
星期二, 三月 12, 2024
The Orange Book, Patent Cooperation Treaty, Agitation, Administration, Conference call, Type, PCT, Conference, Database, Schizophrenia, Intelligence, Caregiver, Webcast, Patient, DSM-IV codes, Neuroscience, Fast Track, Food and Drug Administration, CMC, Wind, Orange Book, SCNC, Positive, Microsatellite instability, Dexmedetomidine, Clinical trial, Therapy, Safety, Patent, Research and development, Collection, FDA, Approved drug, Dementia, CAD, Food, Pharmaceutical industry

NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provided an update on its late-stage TRANQUILITY and SERENITY clinical programs. In addition, the Company reported its financial results for the fourth quarter and full year 2023.

Key Points: 
  • In addition, the Company reported its financial results for the fourth quarter and full year 2023.
  • Net Revenue: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
  • Net Loss: BioXcel Therapeutics had a net loss of $22.3 million for the fourth quarter of 2023, compared to a net loss of $54.8 million for the same period in 2022.
  • ET to provide an update on recent operational highlights and to discuss its fourth quarter and full year 2023 financial results.

Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics

Retrieved on: 
星期三, 四月 3, 2024
Oncology, Health, Health Technology, Genetics, Other Science, Research, Science, Genomics, IHC, Methylation, Partnership, Laser, TMB, NGS, MSI, DNA, Biomarker, Cancer, Hydrofluoroolefin, Biology, Medicine, Imperial College London, AACR, Microsatellite instability, Neoplasm, Therapy, Agilent Technologies, Liquid biopsy, Machine learning, RNA-Seq, University of Oxford, CMO, Medical imaging

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .
  • Agilent Avida - Agilent Avida’s new cutting-edge target enrichment solutions enable simultaneous DNA and methylation profiling from a single sample.
  • Agilent SureSelect Cancer Custom panels - Agilent SureSelect Cancer Custom panels offer the ability to add new and emerging biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), to custom tumor genomic profiling assays.
  • AACR attendees can also explore multiple Agilent research posters and over 50 additional customer posters highlighting Agilent instruments and solutions.

GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
星期一, 四月 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Tempus, Survival, Colorectal cancer, Patient, RNA, MSI, FOLFIRINOX, PDAC, Medicine, Section 42, News, AACR, Microsatellite instability, Therapy, Cancer

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
  • Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition.
  • A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus.
  • Details of the AACR presentations are as follows:
    Session: PO.CL01.01 – Diagnostic Biomarkers 1, Section 42
    The posters will be accessible under the News & Events section of the Company’s website following the conference.

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

Retrieved on: 
星期二, 三月 26, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Oncology, NCI, Combination, Gene, ECOG, Physician, Patient, Malignancy, NGS, Biomarker, Research, DNA, RNA, Tumor microenvironment, National Cancer Institute, WES, Cancer, MD, Medicine, Microsatellite instability, Clinical trial, RNA-Seq, Bangladesh Technical Education Board, Drug resistance

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
  • ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial.
  • Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.
  • “Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
星期三, 三月 6, 2024
WBC, WRN, Lung cancer, RNA, Malignancy, Microsatellite instability, Proteome, Intellectual property, MMR, MPN, Glioblastoma, Neoplasm, Splenomegaly, DMPK, Phosphorylation, HDAC, STAT5, RNA-Seq, WES, Standard of care, Therapy, RecQ helicase, Phenotype, Ruxolitinib, DNA, DNA repair, Pancreatic serous cystadenoma, CDKN2A, Cancer, CRC, PIM, Arginine, MTA, Abstract, PDC, MTAP, Colorectal cancer, CRISPR, PV, MF, MSI-H, Cell, JAK, DNA mismatch repair, Medicine, Patient, Gene, PRMT5, Haematopoiesis, Mesothelioma, Pharmaceutical industry

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Retrieved on: 
星期一, 二月 12, 2024
New product development, American Cancer Society, SCNC, Medicine, Prostate cancer, Intelligence, Adenocarcinoma, FDA, Food, CPI, Therapy, Patient, Microsatellite instability, Survival, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of BXCL701 in combination with a CPI for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions, fill unmet medical needs, and bring promising medicines to patients more quickly. Therapies granted this designation are given the opportunity for more frequent interactions with the FDA, a rolling review, and potential eligibility for accelerated approval and priority review. 

Key Points: 
  • The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions, fill unmet medical needs, and bring promising medicines to patients more quickly.
  • Therapies granted this designation are given the opportunity for more frequent interactions with the FDA, a rolling review, and potential eligibility for accelerated approval and priority review.
  • At the same time, it further validates the unique AI-based drug re-innovation approach that we used to discover this asset,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics.
  • “We are encouraged by the potential of BXCL701, which has demonstrated clinical proof of concept in both SCNC and adenocarcinoma.

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

Retrieved on: 
星期二, 一月 16, 2024
Research, Medical Devices, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, MSI, LCD, Patient, Form 1095, PSNL, DNA, Medicare, RNA, DX, TMB, Genomics, NeXT, Transcriptome, Microsatellite instability, FDA, Biomarker, Palmetto, Clinical trial, Physician, Health insurance

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay , providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay , providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.
  • Matching patients to their optimal cancer therapy requires a testing platform that can accurately report a broader range of clinically actionable genomic alterations.
  • Coverage for NeXT DX was extended effective August 29, 2023, under the Palmetto GBA MolDx program foundational Local Coverage Determination (LCD) L38119 (“Next-Generation Sequencing for Solid Tumors”).
  • Personalis estimates that approximately half of new solid tumor cancer cases will be diagnosed in patients covered by Medicare.

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

Retrieved on: 
星期三, 十二月 20, 2023
Myriad, HRD, Medicine, MYGN, Research, Fox Chase Cancer Center, MSI, Health, IRB, Genetics, Cancer, DNAnexus, TMB, Myriad Genetics, Institutional review board, Genetic testing, Patient, Microsatellite instability, MCRR, Pharmaceutical industry

SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).

Key Points: 
  • SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).
  • The latest enhancements make the MCRR one of the largest pan-cancer registries freely available for research use and supports transparent clinical data sharing to advance the field.
  • Built on DNAnexus, a leading enterprise Precision Health platform, the MCRR provides a secure and easy-to-use interface for scientific data analysis, collaboration, and discovery.
  • Myriad is accepting research concept forms from individuals and institutions seeking to undertake research projects.

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Retrieved on: 
星期二, 十一月 14, 2023
Doctor of Philosophy, Bispecific monoclonal antibody, Pancreatic cancer, MSI, Brain, Research, Annual general meeting, Glioblastoma, Metalloproteinase, Toronto Stock Exchange, Patient, MDNA, Pakistan Society of Neuro-Oncology, Intellectual property, Pembrolizumab, OTC Markets Group, Neuro-Oncology (journal), Conference, Standard of care, Melanoma, SITC, Survival, Partnership, Cancer, Neoplasm, Bifunctional, TSX, SNO, Microsatellite instability, Decompression (diving), Society, MMR, Patent, Pharmaceutical industry, Cryptocurrency, Immunotherapy

TORONTO and HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA; OTC: MDNAF), a clinical-stage company focused on the design and development of novel evolutionary superkines to create revolutionary immunotherapies, today announced financial results and corporate highlights for the second quarter of fiscal 2024, ended September 30, 2023.

Key Points: 
  • We look forward to reporting initial Phase 2 dose expansion data from both the monotherapy and combination arms during the first half of 2024,” concluded Dr.
  • Clinical update from the ABILITY study’s MDNA11 plus pembrolizumab Phase 2 combination arm expected in the first half of 2024.
  • Research and development expenses of $3.1 million were incurred during the quarter ended September 30, 2023, compared with $2.4 million incurred in the quarter ended September 30, 2022.
  • General and administrative expenses of $2.3 million were incurred during the quarter ended September 30, 2023, compared with $2.4 million during the quarter ended September 30, 2022.